Advocate Illinois Masonic Medical Center — Chicago, Illinois

Advocate Illinois Masonic Medical Center is a clinical research site located in Chicago, Illinois, United States 60657.

Crixeo Clinical Trials Trust Score: 33/100 (FAILING). This profile has not yet been claimed by the site owner.

Advocate Illinois Masonic Medical Center has participated in 143 clinical trials with 113 currently active.

Therapeutic areas: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8.

Sponsors: National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group, Alliance for Clinical Trials in Oncology.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Chicago

Browse all research sites in Illinois · View every site in Chicago

Sponsor Feasibility Report

Trust Score: 33/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Advocate Illinois Masonic Medical Center?

Advocate Illinois Masonic Medical Center has a Crixeo Trust Score of 33/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Advocate Illinois Masonic Medical Center conducted?

Advocate Illinois Masonic Medical Center has 143 clinical trials on record, with 113 currently active. Their work covers Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8.

Is Advocate Illinois Masonic Medical Center accredited by Crixeo Clinical Trials?

Advocate Illinois Masonic Medical Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Advocate Illinois Masonic Medical Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.